Original Article
European Journal of Clinical Nutrition (2007) 61, 536–541. doi:10.1038/sj.ejcn.1602553; published online 29 November 2006
Efficacy of 
s1-casein hydrolysate on stress-related symptoms in women
J H Kim1, D Desor2, Y T Kim3, W J Yoon3, K S Kim4, J S Jun5, K H Pyun1 and I Shim1
- 1Department of Integrative Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Laboratoire de Neurosciences Comportementales, Unité de recherche sur l'Animal et les Produits Animaux, Université Henri Poincaré, Institut National Polytechnique de Lorraine/Institut National de la Recherche Agronomique, Faculté des Sciences, Vandoeuvre Les Nancy Cedex, France
- 3Department of Pharmaceuticals and Health Foods, Lotte R&D Center, Seoul, Korea
- 4Department of Family Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 5Department of Psychiatry, Inha University Hospital, Incheon, Korea
Correspondence: Dr I Shim, Department of Integrative Medicine, College of Medicine, The Catholic University of Korea, 505 Banpo-Dong, Seocho-Ku, Seoul 137-701, Korea. E-mail: ishim@catholic.ac.kr
Received 15 August 2005; Revised 4 September 2006; Accepted 25 September 2006; Published online 29 November 2006.
Abstract
Objective:
To examine the effects of 
s1-casein hydrolysate on females with stress-related symptoms.
Design:
Double-blind, randomized, crossover, placebo-controlled trial.
Setting:
The
s1-casein hydrolysate was manufactured by INGREDIA (Arras, France) and the placebo was manufactured by DIETAROMA (Bourg, France). Study was designed and performed at PROCLAIM (Rennes, France), and the statistical analyses were performed by D Desor (Nancy, France).
Subjects:
A total of 63 female volunteers suffering from at least one disorder that may be related to stress such as anxiety, sleep problems and general fatigue.
Interventions:
A total of 63 volunteers participated in a double-blind, randomized, crossover, placebo-controlled study. Subjects were randomly allocated to receive either tablets containing
s1-casein hydrolysate or placebo at the dose of 150 mg/day for 30 days. After a 3 weeks washout period, they were crossed over for a new 30-day period of tablets intake. The outcome measure was a questionnaire including 44 items of symptoms that may be related stress in which the severity of each sign was evaluated using a 10-degree scale. These measures were studied repeatedly at the day of 0, 15 and 30 after the start of each interventional period.
Results:
The 30-day treatment by
s1-casein hydrolysate in females with stress-related symptoms reduced their symptoms, particularly in digestion (P<0.01), cardiovascular (P<0.05), intellectual (P<0.01), emotional (P<0.05) and social problems (P<0.05).
Conclusion:
This study showed that a 30-day ingestion of
s1-casein hydrolysate decreased the stress-related symptoms in females suggesting that this product may be used as an effective functional ingredient alleviating such symptoms.
Sponsorship:
This study was partially supported by the INGREDIA of France and Neurobiology Research Program from the Korea Ministry of Science and Technology (2004-01757) of Korea.
Keywords:
casein, s1-casein hydrolysate, stress, anxiety, women
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Trinucleotide expansion in haploid germ cells by gap repair
Nature Genetics Letter (01 Apr 2001)
Neuropsychopharmacology Original Article
Efficacy of αs1-casein hydrolysate on stress-related symptoms in women
European Journal of Clinical Nutrition Original Article
